Boston Scientific to Acquire Axonics for $3.7B

TL;DR

BSX is buying Axonics for $3.7B to boost its urology business. Deal expected to close H1 2025.

AI Summary

Boston Scientific Corporation announced on November 19, 2024, that it has entered into a definitive agreement to acquire Axonics, Inc. for approximately $3.7 billion in cash. The acquisition is expected to close in the first half of 2025, subject to customary closing conditions, including regulatory approvals and the approval of Axonics stockholders. This strategic move aims to expand Boston Scientific's urology portfolio.

Why It Matters

This acquisition significantly expands Boston Scientific's presence in the urology market, potentially leading to new product offerings and increased competition in the medical device sector.

Risk Assessment

Risk Level: medium — The acquisition is subject to regulatory approvals and stockholder approval, which introduces uncertainty regarding its completion and timing.

Key Numbers

• $3.7B — Acquisition Price (Total cash consideration for Axonics, Inc.)
• H1 2025 — Expected Closing (Anticipated timeframe for the acquisition to be finalized.)

Key Players & Entities

• Boston Scientific Corporation (company) — Acquiring company
• Axonics, Inc. (company) — Target company
• $3.7 billion (dollar_amount) — Acquisition price
• November 19, 2024 (date) — Agreement date
• first half of 2025 (date) — Expected closing period

FAQ

From the Filing

0000885725-24-000081.txt : 20241122 0000885725-24-000081.hdr.sgml : 20241122 20241122161835 ACCESSION NUMBER: 0000885725-24-000081 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 21 CONFORMED PERIOD OF REPORT: 20241119 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20241122 DATE AS OF CHANGE: 20241122 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BOSTON SCIENTIFIC CORP CENTRAL INDEX KEY: 0000885725 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 042695240 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11083 FILM NUMBER: 241489989 BUSINESS ADDRESS: STREET 1: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 BUSINESS PHONE: 508-683-4000 MAIL ADDRESS: STREET 1: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 8-K 1 bsx-20241119.htm 8-K bsx-20241119 0000885725 false 0000885725 2024-11-19 2024-11-19 0000885725 us-gaap:CommonStockMember 2024-11-19 2024-11-19 0000885725 bsx:SeniorNotedue2027Member 2024-11-19 2024-11-19 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________________________ FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 _____________________________________________________________________ Date of Report (Date of earliest event reported): November 19, 2024 BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-11083 04-2695240 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)      300 Boston Scientific Way , Marlborough , Massachusetts                  01752-1234     (Address of principal executive offices)                           (Zip Code) ( 508 ) 683-4000 (Registrant's telephone number, including area code) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol Name of each exchange on which registered Common Stock, $0.01 par value per share BSX New York Stock Exchange 0.625% Senior Notes due 2027 BSX27 New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company    ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (i) 20